RESUMO
It is now over a decade since the meningococcal B vaccine, MeNZB, was in routine use in New Zealand. From July 2004 until June 2008 it was administered in a three-dose schedule to over a million individuals, aged six weeks to 20 years, to provide protection against the epidemic strain of group B Meningococci. The cost of the campaign, including the development of the vaccine was substantial, in excess of $200M, but it contributed to a reduced incidence of meningococcal infections along with a reduction in morbidity and mortality. The campaign led to the development of a national immunisation register (NIR), which is still in existence today. As well as considering the legacies of the MeNZB vaccination programme, this paper examines whether there are any lessons to be learned, specifically concerning active vaccine safety monitoring, which may be important if, and when, a COVID-19 vaccine is developed and a national immunisation campaign instituted.
